NTRK Fusions in Central Nervous System Tumors: A Rare, but Worthy Target

Colorectal carcinomas containing hypermethylated MLH1 promoter and wild type BRAF/KRAS are enriched for targetable kinase fusions

(2019) Emiliano Cocco et al.   CANCER RESEARCH

Role of osimertinib in the treatment of EGFR-mutation positive non-small-cell lung cancer

(2019) Jennifer W Carlisle et al.   Future Oncology

New fusion sarcomas histopathology and clinical significance of selected entities

(2019) Markku Miettinen et al.   HUMAN PATHOLOGY

Screening for NTRK-rearranged Tumors Using Immunohistochemistry

(2019) Amélie Bourhis et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario

(2019) Alessandro Russo et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Immunohistochemistry Using a Pan-TRK Antibody Distinguishes Secretory Carcinoma of Salivary Gland from Acinic Cell Carcinoma

(2019) Yin P. Hung et al.   HISTOPATHOLOGY

Biomarkers in tumors of the central nervous system - a review

(2019) David Scheie et al.   APMIS

cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAFV600E mutation

(2019) David W. Ellison et al.   ACTA NEUROPATHOLOGICA

High-grade glioneuronal tumor with an ARHGEF2–NTRK1 fusion gene

(2019) Kazuhiko Kurozumi et al.   Brain Tumor Pathology

ATRX immunohistochemistry can help refine ‘not elsewhere classified’ categorisation for grade II/III gliomas

(2019) C. Burford et al.   BRITISH JOURNAL OF NEUROSURGERY

Activity of larotrectinib in TRK fusion cancer patients with brain metastases or primary central nervous system tumors.

(2019) Alexander E. Drilon et al.   JOURNAL OF CLINICAL ONCOLOGY

Testing algorithm for identification of patients with TRK fusion cancer

(2019) Frédérique Penault-Llorca et al.   JOURNAL OF CLINICAL PATHOLOGY

Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from TRK Inhibitor Therapy

(2019) Susan J. Hsiao et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: a short review on the current evidence

(2019) Biagio Ricciuti et al.   OncoTargets and Therapy

Fibroblast Growth Factor Family in the Progression of Prostate Cancer

(2019) Jun Teishima et al.   Journal of Clinical Medicine

ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research

(2019) C Marchiò et al.   ANNALS OF ONCOLOGY

Resistance mechanisms and potent-targeted therapies of ROS1-positive lung cancer

(2019) Annie Roys et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Detection of NTRK Fusions: Merits and Limitations of Current Diagnostic Platforms

(2019) James P. Solomon et al.   CANCER RESEARCH

Effectiveness of Added Targeted Therapies to Neoadjuvant Chemotherapy for Breast Cancer: A Systematic Review and Meta-analysis

(2019) Mona Pathak et al.   Clinical Breast Cancer

The role of molecular genetics in the clinical management of sporadic medullary thyroid carcinoma: A systematic review

(2019) Jonathan Mark Fussey et al.   CLINICAL ENDOCRINOLOGY

Targeting ROS1 Rearrangements in Non-small Cell Lung Cancer: Crizotinib and Newer Generation Tyrosine Kinase Inhibitors

(2019) Tessa A. Morris et al.   DRUGS

Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety

(2019) Valentín García-Gutiérrez et al.   Frontiers in Oncology

A paradigm shift in biomarker guided oncology drug development

(2019) Jan Trøst Jørgensen   Annals of Translational Medicine

MYCN amplification drives an aggressive form of spinal ependymoma

(2019) David R. Ghasemi et al.   ACTA NEUROPATHOLOGICA

Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course

(2019) Annika K. Wefers et al.   ACTA NEUROPATHOLOGICA

Pan-TRK Immunohistochemistry

(2019) Beth T. Harrison et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Pan‐Trk immunohistochemistry is a sensitive and specific ancillary tool in diagnosing secretory carcinoma of salivary gland and detecting ETV 6‐ NTRK 3 fusion

(2019) Bin Xu et al.   HISTOPATHOLOGY

NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls

(2019) James P. Solomon et al.   MODERN PATHOLOGY

Resistance to TRK inhibition mediated by convergent MAPK pathway activation

(2019) Emiliano Cocco et al.   NATURE MEDICINE

Fast-diffusing p75NTR monomers support apoptosis and growth cone collapse by neurotrophin ligands

(2019) Laura Marchetti et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer

(2019) Gonzalo Recondo et al.   CLINICAL CANCER RESEARCH

Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial

(2019) Jaafar Bennouna et al.   Clinical Lung Cancer

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012–2016

(2019) Quinn T Ostrom et al.   NEURO-ONCOLOGY

Targeted fusion analysis can aid in the classification and treatment of pediatric glioma, ependymoma, and glioneuronal tumors

(2019) Jessica A. Lake et al.   PEDIATRIC BLOOD & CANCER

Molecularly Targeted Agents in the Therapy of Pediatric Brain Tumors

(2019) Miriam Bornhorst et al.   PEDIATRIC DRUGS

Molecularly defined diffuse leptomeningeal glioneuronal tumor (DLGNT) comprises two subgroups with distinct clinical and genetic features

(2018) Maximilian Y. Deng et al.   ACTA NEUROPATHOLOGICA

Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors

(2018) Erin R. Rudzinski et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Primary and Metastatic Melanoma With NTRK Fusions

(2018) Cecilia Lezcano et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Evaluation of pan-TRK immunohistochemistry in infantile fibrosarcoma, lipofibromatosis-like neural tumour and histological mimics

(2018) Yin P Hung et al.   HISTOPATHOLOGY

A comprehensive analysis of neurotrophins and neurotrophin tyrosine kinase receptors expression during development of zebrafish

(2018) Valeria Nittoli et al.   JOURNAL OF COMPARATIVE NEUROLOGY

The oncogenic neurotrophin receptor tropomyosin-related kinase variant, TrkAIII

(2018) Antonietta Rosella Farina et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Targetable Gene Fusions Associate With the IDH Wild-Type Astrocytic Lineage in Adult Gliomas

(2018) Sherise D Ferguson et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study

(2018) Theodore W Laetsch et al.   LANCET ONCOLOGY

Mechanisms of receptor tyrosine kinase activation in cancer

(2018) Zhenfang Du et al.   Molecular Cancer

DNA methylation-based classification of central nervous system tumours

(2018) David Capper et al.   NATURE

Novel TLE4-NTRK2 fusion in a ganglioglioma identified by array-CGH and confirmed by NGS: Potential for a gene targeted therapy

(2018) Nitya Prabhakaran et al.   NEUROPATHOLOGY

Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

(2018) Alexander Drilon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Driver Fusions and Their Implications in the Development and Treatment of Human Cancers

(2018) Qingsong Gao et al.   Cell Reports

Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors

(2018) Dazhi Liu et al.   Therapeutics and Clinical Risk Management

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Molecular characterization of cancers with NTRK gene fusions

(2018) Zoran Gatalica et al.   MODERN PATHOLOGY

Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations

(2018) Alexander Drilon et al.   Cancer Discovery

TRK Fusion Cancers in Children: A Clinical Review and Recommendations for Screening

(2018) Catherine M. Albert et al.   JOURNAL OF CLINICAL ONCOLOGY

NTRK fusion-positive cancers and TRK inhibitor therapy

(2018) Emiliano Cocco et al.   Nature Reviews Clinical Oncology

Fibroblast growth factor receptors as treatment targets in clinical oncology

(2018) Masaru Katoh   Nature Reviews Clinical Oncology

Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers

(2018) Robert Roskoski   PHARMACOLOGICAL RESEARCH

TRK Inhibition: A New Tumor-Agnostic Treatment Strategy

(2018) Shivaani Kummar et al.   Targeted Oncology

Comprehensive genomic profiling identifies novel NTRK fusions in neuroendocrine tumors

(2018) Darren S. Sigal et al.   Oncotarget

The transmembrane domain of the p75 neurotrophin receptor stimulates phosphorylation of the TrkB tyrosine kinase receptor

(2017) Khalil Saadipour et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer

(2017) Filippo Pietrantonio et al.   JNCI-Journal of the National Cancer Institute

Activity of Entrectinib in a Patient With the First Reported NTRK Fusion in Neuroendocrine Cancer

(2017) Darren Sigal et al.   Journal of the National Comprehensive Cancer Network

Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers

(2017) Miho J. Fuse et al.   MOLECULAR CANCER THERAPEUTICS

Elements of cancer immunity and the cancer–immune set point

(2017) Daniel S. Chen et al.   NATURE

Targeting Epigenetic Pathways in the Treatment of Pediatric Diffuse (High Grade) Gliomas

(2017) Magimairajan Issai Vanan et al.   Neurotherapeutics

Targeting TRK family proteins in cancer

(2017) Yekaterina B. Khotskaya et al.   PHARMACOLOGY & THERAPEUTICS

The significance of Trk receptors in pancreatic cancer

(2017) Matthew D Johnson et al.   TUMOR BIOLOGY

Somatic chromosomal engineering identifies BCAN-NTRK1 as a potent glioma driver and therapeutic target

(2017) Peter J. Cook et al.   Nature Communications

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

(2017) Alexander Drilon et al.   Cancer Discovery

A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion–Positive Solid Tumors

(2017) Alexander Drilon et al.   Cancer Discovery

Detecting Gene Rearrangements in Patient Populations Through a 2-Step Diagnostic Test Comprised of Rapid IHC Enrichment Followed by Sensitive Next-Generation Sequencing

(2017) Danielle A. Murphy et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer

(2017) Filippo Pietrantonio et al.   JNCI-Journal of the National Cancer Institute

An integrative molecular and genomic analysis of pediatric hemispheric low-grade gliomas: an update

(2016) Alvaro Lassaletta et al.   CHILDS NERVOUS SYSTEM

Neurotrophin signaling endosomes: biogenesis, regulation, and functions

(2016) Naoya Yamashita et al.   CURRENT OPINION IN NEUROBIOLOGY

NTRK3 kinase fusions in Spitz tumours

(2016) Iwei Yeh et al.   JOURNAL OF PATHOLOGY

Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications

(2016) E. Ardini et al.   MOLECULAR CANCER THERAPEUTICS

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer

(2016) J. F. Gainor et al.   Cancer Discovery

Pilocytic astrocytoma: pathology, molecular mechanisms and markers

(2015) V. Peter Collins et al.   ACTA NEUROPATHOLOGICA

Chromosomal rearrangements involving the NTRK1 gene in colorectal carcinoma

(2015) Laurent Créancier et al.   CANCER LETTERS

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors

(2015) D. Ercan et al.   CLINICAL CANCER RESEARCH

Targeting cancer with kinase inhibitors

(2015) Stefan Gross et al.   JOURNAL OF CLINICAL INVESTIGATION

Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer

(2015) Andrea Sartore-Bianchi et al.   JNCI-Journal of the National Cancer Institute

Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF

(2015) J. F. Hechtman et al.   MOLECULAR CANCER RESEARCH

NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line

(2015) Su Jin Lee et al.   Oncotarget

Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer

(2015) Andrea Sartore-Bianchi et al.   JNCI-Journal of the National Cancer Institute

Molecular genetics of ependymomas and pediatric diffuse gliomas: a short review

(2014) Sumihito Nobusawa et al.   Brain Tumor Pathology

Developmental co-expression and functional redundancy of tyrosine phosphatases with neurotrophin receptors in developing sensory neurons

(2014) Viktoria Tchetchelnitski et al.   INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE

The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition

(2014) Elena Ardini et al.   Molecular Oncology

The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma

(2014) Gang Wu et al.   NATURE GENETICS

Anchored multiplex PCR for targeted next-generation sequencing

(2014) Zongli Zheng et al.   NATURE MEDICINE

Methylation and Expression Patterns of Tropomyosin-Related Kinase Genes in Different Grades of Glioma

(2014) Mahalakshmi Palani et al.   NEUROMOLECULAR MEDICINE

NTRK1 Fusion in Glioblastoma Multiforme

(2014) Jinkuk Kim et al.   PLoS One

TERT Promoter Mutations Lead to High Transcriptional Activity under Hypoxia and Temozolomide Treatment and Predict Poor Prognosis in Gliomas

(2014) Chen Chen et al.   PLoS One

Asymmetrical expression of BDNF and NTRK3 genes in frontoparietal cortex of stress-resilient rats in an animal model of depression

(2014) Sara Farhang et al.   SYNAPSE

Receptor Tyrosine Kinases: Legacy of the First Two Decades

(2014) J. Schlessinger   Cold Spring Harbor Perspectives in Biology

The landscape of kinase fusions in cancer

(2014) Nicolas Stransky et al.   Nature Communications

TRKing Down an Old Oncogene in a New Era of Targeted Therapy

(2014) Aria Vaishnavi et al.   Cancer Discovery

Exploration of the gene fusion landscape of glioblastoma using transcriptome sequencing and copy number data

(2013) Nameeta Shah et al.   BMC GENOMICS

ETV6-NTRK3 is a common chromosomal rearrangement in radiation-associated thyroid cancer

(2013) Rebecca J. Leeman-Neill et al.   CANCER

Expression of NTRK1/TrkA affects immunogenicity of neuroblastoma cells

(2013) Kristian W. Pajtler et al.   INTERNATIONAL JOURNAL OF CANCER

The integrated landscape of driver genomic alterations in glioblastoma

(2013) Veronique Frattini et al.   NATURE GENETICS

Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma

(2013) David T W Jones et al.   NATURE GENETICS

Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas

(2013)   NATURE GENETICS

Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer

(2013) Aria Vaishnavi et al.   NATURE MEDICINE

TrkB inhibition as a therapeutic target for CNS-related disorders

(2012) Fabien Boulle et al.   PROGRESS IN NEUROBIOLOGY

Clinical significance of NTRK family gene expression in neuroblastomas

(2011) Jennifer E. Light et al.   PEDIATRIC BLOOD & CANCER

Mammary Analogue Secretory Carcinoma of Salivary Glands, Containing the ETV6-NTRK3 Fusion Gene: A Hitherto Undescribed Salivary Gland Tumor Entity

(2010) Alena Skálová et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Cell Signaling by Receptor Tyrosine Kinases

(2010) Mark A. Lemmon et al.   CELL

Human TrkB gene: novel alternative transcripts, protein isoforms and expression pattern in the prefrontal cerebral cortex during postnatal development

(2010) Kristi Luberg et al.   JOURNAL OF NEUROCHEMISTRY

Gustatory papillae and taste bud development and maintenance in the absence of TrkB ligands BDNF and NT-4

(2009) Akira Ito et al.   CELL AND TISSUE RESEARCH

On Trk--The TrkB Signal Transduction Pathway Is an Increasingly Important Target in Cancer Biology

(2009) C. J. Thiele et al.   CLINICAL CANCER RESEARCH

Trk Receptor Expression and Inhibition in Neuroblastomas

(2009) G. M. Brodeur et al.   CLINICAL CANCER RESEARCH

Evidence for a possible association of neurotrophin receptor (NTRK-3) gene polymorphisms with hippocampal function and schizophrenia

(2009) Mona K. Otnæss et al.   NEUROBIOLOGY OF DISEASE

Genetic Association of Neurotrophic Tyrosine Kinase Receptor Type 2 (NTRK2) With Alzheimer's Disease

(2007) Zuomin Chen et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS